Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,867.50
-4.2683-0.23%
Number of Gainers:5
Number of Losers:14
Number of Flat:- -
PE:- -
High:1,871.60
Open:1,870.34
Low:1,853.56
Close:1,871.77
Volume:134.66M
Turnover:8.34B
Market Cap:1.52T
Float Cap:1.48T

Loading ...

Ibio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 28

Press Release: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 28

Gilead Breaks Ground on Foster City Biologics Facility in $32 Billion US Investment Push

Reuters
·
Aug 28

Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares

Reuters
·
Aug 28

Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV

TIPRANKS
·
Aug 28

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens

THOMSON REUTERS
·
Aug 28

Sanofi Spokesperson Says Nuvaxovid to be Available Across U.S. for 2026-27 Respiratory Virus Season

Reuters
·
Aug 28

NYSE Most Active Issues

Dow Jones
·
Aug 28

Inovio Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Aug 28

Abbott CEO Robert B. Ford Disposes of $ US 46.17 Million in Common Shares

Reuters
·
Aug 28

FDA Approves Seasonal Covid-19 Vaccines from Moderna, Pfizer, BioNTech

Dow Jones
·
Aug 28

Pfizer and BioNTech receive FDA approval for XFG-adapted COVID-19 vaccine

TIPRANKS
·
Aug 28

Moderna Inc. Stock Slips 4.6%, Underperforms Peers

Dow Jones
·
Aug 28

Pfizer, BioNTech Win FDA Approval for XFG-Adapted COVID-19 Vaccine in High-Risk US Adults

Reuters
·
Aug 28

Pfizer - Shipping of Xfg-Adapted Covid-19 Vaccine to Begin Immediately

THOMSON REUTERS
·
Aug 28

Pfizer - 2026-2027 Covid-19 Vaccine Formula Targets Xfg Variant Per FDA Guidance

THOMSON REUTERS
·
Aug 28

Moderna Wins FDA Approval for Updated 2026-2027 COVID-19 Vaccines Targeting JN.1-Lineage XFG Subvariant

Reuters
·
Aug 28

Moderna - FDA Approved Sbla for 2026-2027 Formulas for Spikevax and Mnexspike

THOMSON REUTERS
·
Aug 28

Moderna - Updated Formula for Spikevax is NOW Approved for Individuals 6 Months Through 64 Years of Age with at Least One Underlying Condition

THOMSON REUTERS
·
Aug 28

Moderna: Updated Covid-19 Vaccines Expected Available in Coming Days

THOMSON REUTERS
·
Aug 28